Delve Detect Enables Neurologists to Treat CNS Infections When Conventional Testing Fails
Delve Bio will showcase new data on its metagenomic sequencing service, Delve Detect, at the American Academy of Neurology 2026 meeting. A head‑to‑head study showed the test matches standard CNS panels while uncovering additional pathogens and co‑infections. Clinical cases highlighted how Delve Detect identified HSV‑1 in a toddler and pinpointed causative organisms in ventriculitis and brain‑abscess patients where conventional tests were negative. Results are delivered within a day and include review by an on‑call microbial sequencing board.
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
Fulgent Genetics announced it will publish its first‑quarter 2026 financial results before the market opens on Friday, May 1, 2026. The company will host an investor conference call at 8:30 AM ET to discuss the numbers and answer questions. Fulgent’s business spans laboratory services...
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform
Foundation Medicine announced the integration of SAGA Diagnostics' Pathlight tumor‑informed molecular residual disease (MRD) platform following Roche's definitive agreement to acquire SAGA for up to $595 million. Pathlight leverages whole genome sequencing and digital PCR to detect structural variants with ultra‑sensitive...
Registrar Corp Acquires Dell Tech, Expanding Canadian Regulatory Expertise and Strengthening Global Market Access Solutions
Registrar Corp announced the acquisition of Dell Tech, a Canada‑based regulatory consulting firm, to deepen its expertise in Health Canada requirements. The deal adds Dell Tech’s 45‑year track record in product licensing, safety, and laboratory services to Registrar’s portfolio serving 35,000 clients...
Promega to Showcase Oncology Research Tools and Companion Diagnostics at AACR Annual Meeting 2026
Promega will showcase a suite of oncology‑focused tools at the AACR Annual Meeting in San Diego, including its Lumit® hKi‑67 proliferation assay, the TarSeer™ BRETSA™ target‑engagement platform, and FDA‑cleared OncoMate® MSI companion diagnostic. The company also unveiled pre‑configured automated nucleic‑acid...
Organon’s VTAMA® (Tapinarof) Cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
Organon announced that its steroid‑free VTAMA® (tapinarof) 1% cream received a strong, evidence‑based recommendation in the American Academy of Dermatology’s 2026 pediatric atopic dermatitis (AD) guidelines. The AAD highlighted VTAMA as the only topical treatment with high‑certainty evidence that is...
Elucid Announces Commercial Availability of Lesion Inspection Tool for Plaque-IQ™
Elucid announced the commercial launch of a Lesion Inspection Tool within its Plaque‑IQ software, enabling physicians to quantify plaque composition at the individual lesion level in coronary and carotid arteries. The tool provides quantitative data on high‑risk features such as...
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Precision BioSciences received Clinical Trial Application approval to add sites in France and Romania to its global ELIMINATE‑B study of PBGENE‑HBV, an in‑vivo gene‑editing therapy for chronic hepatitis B. The expansion joins existing locations in the United Kingdom, Moldova, New Zealand, Hong Kong...
Global E·dentity™ Expands Landmark CRADA with DHS & TSA, Powered by President Trump’s Visionary Leadership to Secure America’s National Identity...
Global e·dentity™ Inc., a service‑disabled veteran‑owned firm, announced an amendment (AM01) to its CRADA with DHS and TSA that adds a new Personally Identifiable Information phase focused on privacy‑first biometric digital ID development. The amendment extends the partnership, enabling the...
HYROX and Amazfit Strengthen Alliance With Global Three-Year Partnership
Amazfit, the wearable brand of Zepp Health, announced a three‑year global partnership with HYROX, expanding a prior regional collaboration. The deal adds smart rings, glasses, cameras, and straps to HYROX’s athlete toolkit, alongside dedicated training modes and data integrations. HYROX...
Amadeus Travel Dreams 2026: How AI, Mental Wellbeing, and Sustainability Are Redefining Travel Value
Amadeus' Travel Dreams 2026 study of 6,000 travelers shows mental wellbeing now drives travel choices, with 41% seeking a calmer nervous system. Hotels can unlock up to $1 million extra annual revenue per 150‑room property by retailing six high‑demand attributes such as...
Atelerix Forms Strategic Partnership With JH Health Ltd to Expand Non-Cryogenic Cell Preservation Capabilities in the Middle East
Atelerix, a UK biotech, has signed a strategic partnership with Saudi Arabia’s JH Health Ltd, granting JH Health exclusive rights to distribute Atelerix’s non‑cryogenic hydrogel cell‑preservation solutions across the Middle East. The deal includes funding for high‑volume local manufacturing, regulatory...
Leukogene Therapeutics Announces Two Presentations at the AACR Annual Meeting 2026 Highlighting MHC Class II-Engager Immunotherapies
Leukogene Therapeutics announced two poster presentations at the 2026 AACR Annual Meeting in San Diego, showcasing its MHC class II‑engager immunotherapy candidates for acute myeloid leukemia and pancreatic cancer. The posters will be displayed during the Immunology session on bi- and...
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Who...
Daiichi Sankyo and Merck have received FDA acceptance and Priority Review for the Biologics License Application of ifinatamab deruxtecan, a first‑in‑class B7‑H3‑directed antibody‑drug conjugate, targeting adult patients with extensive‑stage small cell lung cancer (ES‑SCLC) who progressed after platinum chemotherapy. The...
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
Personalis will showcase its ultrasensitive NeXT Personal ctDNA assay at the AAC 2026 meeting, including an oral presentation on neoadjuvant pembrolizumab in high‑risk colorectal cancer. The company will also debut Real‑Time Variant Tracker, a new MRD test option that longitudinally monitors therapy‑resistance...
Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology
Almirall, a global medical dermatology company, has expanded its partnership with the Barcelona Supercomputing Center (BSC) under the BSC Connects program. The new framework, running through 2026, gives Almirall access to BSC’s AI and high‑performance computing resources, including the MareNostrum 5...
Trinity Launches InsightsEDGE™ | Digital Twins — Generative AI Unlocks Always-On Intelligence for Life Sciences Commercial Teams
Trinity announced the general availability of InsightsEDGE | Digital Twins, an AI‑powered platform that creates interactive virtual replicas of healthcare professionals, patients, and payers. The solution leverages Trinity’s 30‑year research pedigree and its proprietary Weave data fabric to continuously ingest claims, EMR,...
Corcept Presents Complete Data From Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus...
Corcept Therapeutics presented final overall survival results from the phase 3 ROSELLA trial, showing that Lifyorli™ (relacorilant) combined with nab‑paclitaxel cuts the risk of death by 35 percent and adds 4.1 months to median survival versus chemotherapy alone. The regimen met both overall...
Prothena Announces Leadership Team Updates
Prothena Corp. announced two senior leadership promotions. Annie Kingston, previously VP of Corporate Strategy, is now Chief Strategy Officer, responsible for growth strategy and the CYTOPE® platform. Michael Isaacs, who has been Deputy General Counsel since 2020, will step into...
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
NeuroPace, the maker of the RNS System for drug‑resistant epilepsy, announced that its executive team will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026. The session will be streamed live and a replay will be available...
Covalon to Showcase Clinical Innovation and Infection Prevention Leadership at Infusion Nurses Society 2026 Annual Meeting
Covalon Technologies Ltd. announced its participation in the Infusion Nurses Society (INS) 2026 Annual Meeting in Louisville, Kentucky, from April 11‑14. The company will showcase its VALGuard Vascular Access Line Guard and CovaClear IV Cover dressings, emphasizing solutions that protect...
ISG to Study Medical Device Digital Service Providers
Information Services Group (ISG) announced a new Provider Lens® research series called Medical Device Digital Services, scheduled for release in October 2026. The study surveyed over 100 service providers that help medical‑device manufacturers embed AI, cloud, and IoT capabilities into their...
MediStreams Achieves Clean SOC 2 Type II Certification, Strengthening Security in Healthcare Revenue Cycle Management and Payment Automation
MediStreams announced it has received a clean SOC 2 Type II audit for the full 2025 calendar year, covering Security, Availability, and Processing Integrity. The unqualified opinion was issued by independent CPA firm Aprio LLP after a year‑long assessment of its payment‑posting...
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (Avutometinib Capsules; Defactinib Tablets) in Recurrent Low-Grade Serous...
Verastem Oncology presented two‑year median follow‑up data from its Phase 2 RAMP 201 trial of the AVMAPKI® FAKZYNJA® combination (avutometinib + defactinib) in recurrent low‑grade serous ovarian cancer (LGSOC). The updated analysis confirmed a median duration of response of 31.1 months and a median progression‑free survival...
Bial Launches Education and Awareness Campaign for World Parkinson’s Day
Bial, the Portuguese biopharma focused on neuroscience, has launched “Dialogues with Parkinson’s,” a year‑long education campaign in partnership with Parkinson’s Europe. The initiative aims to improve communication among patients, caregivers and clinicians to promote earlier diagnosis, especially for the 10‑20%...
Ossium Health Hosts Facility Tour and Reception for Indiana Governor Mike Braun and Healthcare Leaders
Ossium Health hosted a facility tour and reception with Indiana Governor Mike Braun, showcasing its 34,000‑square‑foot Indianapolis plant that houses five ISO 7 cleanrooms and a bone‑marrow banking platform. The company has treated 23 patients using organ donor‑derived bone marrow, underscoring...
New Billboards Tout AHF as Top HIV Provider, Promote STD Testing
AIDS Healthcare Foundation (AHF) launched two national outdoor campaigns, branding itself as “America’s #1 HIV Provider” and promoting free STD testing through the “Peace of Mind” theme. The first campaign highlights AHF’s care for over 234,000 patients across 19 states,...
Vedanta Biosciences Showcases Innovative Work on Its Microbiome-Based Therapeutics at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)...
Vedanta Biosciences presented a poster on its eight‑strain consortium VE303 and an oral talk on VE707 at the ESCMID 2026 Congress in Munich. VE303 showed more than an 80% reduction in recurrent Clostridioides difficile infection odds in a Phase 2 trial...
Concentra to Announce First Quarter 2026 Results on Thursday, May 7, 2026
Concentra Group Holdings (NYSE: CON) will release its first‑quarter 2026 earnings on May 7, 2026, after market close, followed by a live webcast earnings call on May 8. The company, the nation’s largest occupational health provider, operates 628 health centers, 411 onsite...
Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association
Charles River Laboratories announced a partnership with the American Heart Association to back its Heart of Boston campaign, targeting cardiovascular disease awareness and prevention. The collaboration aligns with Charles River’s corporate purpose of creating healthier lives and its broader citizenship...
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
TriSalus Life Sciences will present new pre‑clinical and clinical data on its Pressure Enabled Drug Delivery™ (PEDD) platform at the Society of Interventional Radiology 2026 Annual Scientific Meeting in Toronto. The company’s posters and sessions will cover hepatic tumor penetration...
MDRXLaw Launches MDRXResolve: A Smart, Efficient Alternative to Litigation for Healthcare Disputes
MDRXLaw introduced MDRXResolve, a mediation platform tailored for healthcare providers, offering a discreet, efficient alternative to litigation. The service addresses partnership, contractual, regulatory, and employee disputes, aiming to cut costs, reduce delays, and protect operational continuity. Leveraging MDRXLaw’s experience, the...
Athenahealth Targets AI-Driven Patient Discovery with New Rater8 Reputation Management Integration
athenahealth has embedded rater8’s AI‑powered reputation management directly into its athenaOne EHR platform, allowing ambulatory practices to capture reviews, monitor sentiment, and manage directory listings without leaving their clinical workflow. The move is part of athenahealth’s new Alliance Partnerships program,...
Agape Care Group Named USA Today’s Top Workplace for 3rd Consecutive Year
Agape Care Group was named a USA TODAY Top Workplace for the third straight year, based on third‑party employee engagement data from Energage. The hospice provider also earned Top Workplace Culture Excellence Awards across categories such as purpose, wellbeing and...
GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More...
GoodRx announced a partnership with Eli Lilly to offer the newly FDA‑approved oral GLP‑1 drug Foundayo (orforglipron) at a self‑pay price of $149 per month. The platform is also rolling out self‑pay pricing for Lilly’s injectable Zepbound (tirzepatide) KwikPen at $299...
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Sensei Biotherapeutics announced it will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026. The webcast will be streamed live at 12:45 p.m. ET with a 90‑day replay window. Executives will detail the company’s lead PIKTOR program for endometrial...
NEUPATH HEALTH TO PRESENT AT THE 2026 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE
NeuPath Health Inc. announced that CEO Stephen Lemieux will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 22, 2026. The 30‑minute virtual session, streamed from the Metro Toronto Convention Centre, will include a live Q&A...
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise
Cartography Biosciences announced that Gilead Sciences exercised its first option to exclusively license a novel oncology target identified through Cartography’s ATLAS and SUMMIT single‑cell platforms. The target is part of a multi‑year collaboration aimed at tumor‑selective antigens in triple‑negative breast...
Orthofix Realigns Spine Leadership to Strengthen Focus and Execution
Orthofix Medical announced a strategic realignment of its Spine leadership, eliminating the President, Global Spine Solutions role and placing senior executives directly under CEO Massimo Calafiore. Shaeffer Bannigan now oversees overall Spine strategy, while Mark Sienkiewicz and John Winge focus...
MediFind Becomes First Doctor Directory to Receive the Digital Medicine Society Seal
MediFind, the data‑driven online provider directory owned by Phreesia, has become the first doctor directory to earn the Digital Medicine Society (DiMe) Seal. The seal recognizes platforms that meet rigorous standards for clinical evidence, privacy, security, and usability. MediFind leverages...
Latigo Biotherapeutics Appoints Sara M. Bonstein to Its Board of Directors and as Audit Committee Chair
Latigo Biotherapeutics announced that Sara M. Bonstein, CFO of Insmed, has been appointed as an independent director and chair of its audit committee. Bonstein brings more than two decades of biotech financial leadership, having raised over $4 billion for life‑science companies....
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
Precision BioSciences (NASDAQ: DTIL) announced it will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 9:30 am ET. The virtual session will showcase the company’s ARCUS® gene‑editing platform and its in‑vivo therapeutic pipeline, including programs...
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
Bausch + Lomb received FDA 510(k) clearance for its Bi‑Blade™+ dual‑port vitrectomy cutter and the Adaptive Fluidics update on the Stellaris Elite system. The new cutter operates at 25,000 cuts per minute, a 66% speed boost over the prior model, and delivers a...
Americhem Announces Expansion of Global Healthcare Footprint with New China Investment at Chinaplas 2026
Americhem announced a new clean‑compounding facility in Suzhou, China, slated for the second half of 2026. The plant will be built to ISO 13485 and cGMP standards, extending the company’s regulated healthcare polymer network into Asia. At Chinaplas 2026 the firm will...
VION Biosciences Closes Acquisition of CTL, Strengthening Functional Immune Monitoring Capabilities
VION Biosciences announced the closing of its acquisition of Cellular Technology Limited (CTL), adding ELISPOT and FluoroSpot analyzers, software, consumables, and assay services to its portfolio. The deal enhances VION’s ability to provide functional immune‑monitoring solutions across translational and clinical...
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
Hemispherian AS announced the initiation of a first‑in‑human Phase 1/2a trial of GLIX1 in patients with recurrent glioblastoma and other high‑grade gliomas. GLIX1 is an oral, first‑in‑class small‑molecule TET2 activator that induces tumor‑selective DNA damage and has demonstrated potent preclinical efficacy,...
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Glaukos Corporation will present a slate of scientific abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) meeting in Washington, D.C., and will exhibit at booth #407. The company is also sponsoring an educational symposium on Epioxa™,...
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
Bausch + Lomb announced it will present 45 scientific papers and posters at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., from April 9‑13, 2026. The sessions will feature data on its ELIOS minimally‑invasive...
MedTech Innovator Radar Forum April 7-9 Levels Up MedTech Industry’s Most Rigorous Evaluation Platform and Leading Accelerator Program
MedTech Innovator is debuting the Radar Forum, a single, invite‑only event held April 7‑9, 2026 in Manhattan Beach that replaces its previous multi‑city road‑tour pitches. The three‑day forum will host roughly 500 attendees, including 300 top experts who will evaluate the top...
Spacelabs Healthcare Announces Agreement to Provide Its Rothman Index® to Hospitals and Health Systems Through DEPTH Health
Spacelabs Healthcare has signed an agreement with DEPTH Health to integrate its Rothman Index into DEPTH’s Real‑Time Advisor for Clinical Expert Routing (RACER) platform. The Rothman Index aggregates 26 clinical data points into a 200‑point risk score that updates continuously,...